与胰腺疾病风险相关的增强剂的预测优先级
Li Wang1, Songjoon Baek1, Gauri Prasad2
1Laboratory of Receptor Biology and Gene Expression, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Cell genomics
|October 17, 2025
概括
这项研究绘制了人类胰腺中增强剂-促进剂相互作用的地图,以了解疾病遗传学. 新的模型将遗传变异与胰腺癌风险联系起来,揭示了对调节元件功能的洞察力.
科学领域:
- 基因组学和表观遗传学
- 系统生物学 系统生物学
- 计算生物学 计算生物学
背景情况:
- 增强剂的遗传和表观遗传变异与疾病易感性有关.
- 将增强剂连接到它们的基因和预测增强剂功能障碍是遗传学研究中的重大挑战.
研究的目的:
- 绘制人类胰腺在不同细胞类型和捐赠者的增强剂-促进剂相互作用的地图.
- 开发增强器功能的预测模型及其对细胞类型特定基因表达的贡献.
- 调查胰腺疾病遗传学中的调节要素的作用,包括胰腺管道腺癌 (PDAC).
主要方法:
- 利用3D染色体测定来绘制人类胰腺样本中的增强剂-促进剂相互作用.
- 开发了增强剂-促进剂树模型和机器学习算法,以分析全基因组增强剂连接性并预测基因表达.
- 使用CRISPR干扰和单细胞RNA光 in situ杂交 (FISH) 进行增强器扰动的实验验证.
主要成果:
- 在人类胰腺中生成了增强剂-促进剂相互作用的定量,全基因组地图.
- 机器学习模型准确估计了增强剂对细胞类型特定基因表达的贡献.
- 与胰腺疾病相关的生殖线风险变异与候选基因有关,在PDAC风险的acinar调节元素中显著丰富.
结论:
- 开发的增强器-促进器树模型为分析增强器功能和连接提供了强大的资源.
- 这些模型促进了与疾病相关的遗传变异的注释,将它们与特定的目标基因联系起来.
- 这些发现挑战了PDAC的管状细胞起源模型,突出了性调节元素在疾病风险中的作用.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:12Hazard Ratio
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
For example, in a clinical trial evaluating a...